• If you are wondering whether Danaher is starting to look interesting at its current share price, you are not alone. This article focuses squarely on what you might be paying for the business.
• The stock last closed at US$174.92, with returns of a 2.2% decline over 7 days, a 9.0% decline over 30 days, a 24.1% decline year to date and an 8.8% decline over the past year, which may have changed how the market views its potential and risk.
• Recent share price pressure has arrived alongside ongoing interest in large, diversified life sciences and diagnostics groups like Danaher, as investors reassess how much they are willing to pay for quality and resilience. Broader sector sentiment and shifting expectations around growth, capital allocation and acquisitions have all fed into how the stock is currently priced.
• On Simply Wall St's 6 point valuation checklist, Danaher scores 4 out of 6. The rest of this article will walk through what that means across different valuation methods, before ending with a broader way to think about valuation that goes beyond just the numbers.

Approach 1: Danaher Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today using a required return. It aims to answer what an investor could reasonably pay now for those future cash streams.

For Danaher, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $5.1b. Analysts provide explicit forecasts for several years, and Simply Wall St then extrapolates further, with projected free cash flow reaching about $9.5b in 2035, all expressed in $ and discounted back to today.

Bringing those discounted cash flows together produces an estimated intrinsic value of about $215.58 per share under this DCF model. Against the recent share price of US$174.92, this implies an intrinsic discount of about 18.9%, which indicates Danaher is trading below this model-based estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Danaher is undervalued by 18.9%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Danaher Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it links what you pay directly to the earnings the business is currently generating. It helps you see how many dollars investors are willing to pay today for each dollar of earnings.

What counts as a "normal" or "fair" P/E depends on how the market views a company's growth outlook and risk profile. Higher expected growth or lower perceived risk can support a higher P/E, while slower expected growth or higher risk usually means a lower multiple looks more reasonable.

Danaher currently trades on a P/E of 33.69x. This sits below the Life Sciences industry average P/E of about 37.13x and a peer group average of 37.26x. Simply Wall St also calculates a proprietary "Fair Ratio" for Danaher of 28.43x, which reflects factors such as earnings growth, industry, profit margins, market size and company specific risks. This Fair Ratio can be more tailored than simple peer or industry comparisons because it adjusts for the specific profile of the company rather than assuming all peers deserve similar multiples.

Comparing Danaher’s current P/E of 33.69x with its Fair Ratio of 28.43x suggests the stock screens as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Danaher Narrative

Earlier it was mentioned that there is an even better way to understand valuation, and that is where Narratives come in. They give you a simple way to put your story about Danaher into numbers by linking your view on its future revenue, earnings and margins to a financial forecast, a fair value, and a clear comparison with today’s share price. All of this happens within the Narratives tool on Simply Wall St’s Community page that is used by millions of investors. Each Narrative automatically refreshes when new information such as news or earnings is added. One investor might build a bullish Danaher Narrative that lines up closer to the US$310 analyst target by assuming stronger growth and profitability. Another might build a more cautious Narrative closer to the US$205 target by using more conservative assumptions. Comparing each Fair Value estimate with the current price can then help you decide whether the stock looks attractive, fairly priced, or extended against your own expectations.

Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.